Form 4 for RYTM RHYTHM PHARMACEUTICALS, INC.
Accepted 2025-02-11 00:00:00 ET · period of report 2025-02-09 · accession 0001104659-25-011677 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-02-11 | 2025-02-09+ | RYTM | Lee Jennifer Kayden | EVP, Head of North America | M - OptEx | $6.80 | +9,657 | 6,440 | New | +$65.7K |
| DM | 2025-02-11 | 2025-02-10+ | RYTM | Lee Jennifer Kayden | EVP, Head of North America | S - Sale+OE | $58.63 | -5,216 | 4,409 | -54% | -$305.8K |
| DM | 2025-02-11 | 2025-02-09+ | RYTM | Lee Jennifer Kayden | EVP, Head of North America | M - OptEx | $0.00 | -9,657 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-09 | M | A | 3,437 | — | 4,409 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. |
| 2 | Common | Common Stock | 2025-02-09 | M | A | 4,189 | $6.80 | 8,598 | D | — | — | |
| 3 | Common | Common Stock | 2025-02-10 | S | D | 1,894 | $58.39 | 6,704 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $58.0750 to $58.8900 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote |
| 4 | Common | Common Stock | 2025-02-11 | S | D | 4 | $57.50 | 5,413 | D | — | — | |
| 5 | Common | Common Stock | 2025-02-11 | M | A | 2,031 | — | 6,440 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. |
| 6 | Common | Common Stock | 2025-02-11 | S | D | 1,023 | $57.51 | 5,417 | D | — | — | |
| 7 | Common | Common Stock | 2025-02-10 | S | D | 2,295 | $59.34 | 4,409 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $59.1400 to $59.3600 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote |
| 8 | Derivative | Restricted Stock Units | 2025-02-09 | M | D | 3,437 | $0.00 | 3,437 | D | — · — to — | 3,437 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. (F6) The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. |
| 9 | Derivative | Stock Option (Right to Buy) | 2025-02-09 | M | D | 4,189 | $0.00 | 21,601 | D | $6.80 · — to 2032-02-08 | 4,189 Common Stock | (F7) The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. |
| 10 | Derivative | Restricted Stock Units | 2025-02-11 | M | D | 2,031 | $0.00 | 0 | D | — · — to — | 2,031 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. (F8) The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date. |